A better understanding of the role of the CTLA-CD80/86 axis in the treatment of autoimmune diseases
© 2023 John Wiley & Sons Ltd..
Autoimmune diseases are diseases in which the regulatory mechanisms of the immune response are disturbed. As a result, the body loses self-tolerance. Since one of the main regulatory mechanisms of the immune response is the CTLA4-CD80/86 axis, this hypothesis suggests that autoimmune diseases potentially share a similar molecular basis of pathogenesis. Hence, investigating the CTLA4-CD80/86 axis may be helpful in finding an appropriate treatment strategy. Therefore, this study aims to investigate the molecular basis of the CTLA4-CD80/86 axis in the regulation of the immune response, and then its role in developing some autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. As well, the main therapeutic strategies affecting the CTLA4-CD80/86 axis have been summarized to highlight the importance of this axis in management of autoimmune diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Cell biochemistry and function - 42(2024), 1 vom: 24. Jan., Seite e3895 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Darvish, Zahra [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigens, CD |
|---|
| Anmerkungen: |
Date Completed 26.01.2024 Date Revised 26.01.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/cbf.3895 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365418005 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365418005 | ||
| 003 | DE-627 | ||
| 005 | 20240126232029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/cbf.3895 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1271.xml |
| 035 | |a (DE-627)NLM365418005 | ||
| 035 | |a (NLM)38050849 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Darvish, Zahra |e verfasserin |4 aut | |
| 245 | 1 | 2 | |a A better understanding of the role of the CTLA-CD80/86 axis in the treatment of autoimmune diseases |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.01.2024 | ||
| 500 | |a Date Revised 26.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 John Wiley & Sons Ltd. | ||
| 520 | |a Autoimmune diseases are diseases in which the regulatory mechanisms of the immune response are disturbed. As a result, the body loses self-tolerance. Since one of the main regulatory mechanisms of the immune response is the CTLA4-CD80/86 axis, this hypothesis suggests that autoimmune diseases potentially share a similar molecular basis of pathogenesis. Hence, investigating the CTLA4-CD80/86 axis may be helpful in finding an appropriate treatment strategy. Therefore, this study aims to investigate the molecular basis of the CTLA4-CD80/86 axis in the regulation of the immune response, and then its role in developing some autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, and multiple sclerosis. As well, the main therapeutic strategies affecting the CTLA4-CD80/86 axis have been summarized to highlight the importance of this axis in management of autoimmune diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a B7 | |
| 650 | 4 | |a CD80 | |
| 650 | 4 | |a CD86 | |
| 650 | 4 | |a CTLA4 | |
| 650 | 4 | |a SLE | |
| 650 | 4 | |a autoimmune disease | |
| 650 | 4 | |a cytokines | |
| 650 | 7 | |a CTLA-4 Antigen |2 NLM | |
| 650 | 7 | |a Antigens, CD |2 NLM | |
| 650 | 7 | |a B7-2 Antigen |2 NLM | |
| 650 | 7 | |a Immunoconjugates |2 NLM | |
| 650 | 7 | |a B7-1 Antigen |2 NLM | |
| 650 | 7 | |a Cell Adhesion Molecules |2 NLM | |
| 700 | 1 | |a Kheder, Ramiar Kamal |e verfasserin |4 aut | |
| 700 | 1 | |a Faraj, Tola Abdulsattar |e verfasserin |4 aut | |
| 700 | 1 | |a Najmaldin, Soran K |e verfasserin |4 aut | |
| 700 | 1 | |a Mollazadeh, Samaneh |e verfasserin |4 aut | |
| 700 | 1 | |a Nosratabadi, Reza |e verfasserin |4 aut | |
| 700 | 1 | |a Esmaeili, Seyed-Alireza |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cell biochemistry and function |d 1984 |g 42(2024), 1 vom: 24. Jan., Seite e3895 |w (DE-627)NLM012967254 |x 1099-0844 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2024 |g number:1 |g day:24 |g month:01 |g pages:e3895 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/cbf.3895 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2024 |e 1 |b 24 |c 01 |h e3895 | ||